Vistagen Therapeutics, Inc. (VTGN)
0.2739
-0.02
(-7.15%)
USD |
NASDAQ |
Sep 25, 16:00
0.263
-0.01
(-3.98%)
After-Hours: 19:59
Vistagen Therapeutics Cash from Operations (Quarterly) : -14.71M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.71M |
| March 31, 2026 | -16.20M |
| December 31, 2025 | -17.63M |
| September 30, 2025 | -13.76M |
| June 30, 2025 | -18.85M |
| December 31, 2024 | -10.28M |
| September 30, 2024 | -10.89M |
| June 30, 2024 | -10.87M |
| March 31, 2024 | -7.197M |
| December 31, 2023 | -4.535M |
| September 30, 2023 | -6.190M |
| June 30, 2023 | -7.891M |
| March 31, 2023 | -7.473M |
| December 31, 2022 | -9.933M |
| September 30, 2022 | -16.34M |
| June 30, 2022 | -15.97M |
| March 31, 2022 | -15.59M |
| December 31, 2021 | -12.05M |
| September 30, 2021 | -11.45M |
| June 30, 2021 | -6.173M |
| March 31, 2021 | -5.282M |
| December 31, 2020 | -4.989M |
| September 30, 2020 | 1.004M |
| June 30, 2020 | -2.807M |
| March 31, 2020 | -2.579M |
| Date | Value |
|---|---|
| December 31, 2019 | -4.280M |
| September 30, 2019 | -4.137M |
| June 30, 2019 | -4.761M |
| March 31, 2019 | -3.557M |
| December 31, 2018 | -3.907M |
| September 30, 2018 | -3.928M |
| June 30, 2018 | -3.135M |
| March 31, 2018 | -2.604M |
| December 31, 2017 | -2.445M |
| September 30, 2017 | -1.876M |
| June 30, 2017 | -2.134M |
| March 31, 2017 | -1.294M |
| December 31, 2016 | -2.095M |
| September 30, 2016 | -2.202M |
| June 30, 2016 | -1.671M |
| March 31, 2016 | -1.310M |
| December 31, 2015 | -1.169M |
| September 30, 2015 | -1.506M |
| June 30, 2015 | -0.8233M |
| March 31, 2015 | -0.8945M |
| December 31, 2014 | -0.341M |
| September 30, 2014 | -0.5216M |
| June 30, 2014 | -1.012M |
| March 31, 2014 | -0.4671M |
| December 31, 2013 | -0.3425M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Onconetix, Inc. | -1.918M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 0.909M |
| Free Cash Flow | -62.38M |
| Free Cash Flow Per Share (Quarterly) | -0.3422 |
| Free Cash Flow to Equity (Quarterly) | -14.45M |
| Free Cash Flow to Firm (Quarterly) | -14.71M |
| Free Cash Flow Yield | -567.3% |